[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @NEJM NEJM NEJM posts on X about events, history, red, education the most. They currently have XXXXXXX followers and XXX posts still getting attention that total XXXXXX engagements in the last XX hours. ### Engagements: XXXXXX [#](/creator/twitter::25950355/interactions)  - X Week XXXXXXX -XX% - X Month XXXXXXX -XXXX% - X Months XXXXXXXXX +67% - X Year XXXXXXXXX -XX% ### Mentions: XX [#](/creator/twitter::25950355/posts_active)  - X Month XX -XX% - X Months XXX +106% - X Year XXX +30% ### Followers: XXXXXXX [#](/creator/twitter::25950355/followers)  - X Week XXXXXXX +0.11% - X Month XXXXXXX -XXXX% - X Months XXXXXXX +0.03% - X Year XXXXXXX -XXXX% ### CreatorRank: XXXXXXX [#](/creator/twitter::25950355/influencer_rank)  ### Social Influence **Social topic influence** [events](/topic/events) #3138, [history](/topic/history), [red](/topic/red), [education](/topic/education), [reduce](/topic/reduce), [what is](/topic/what-is), [express](/topic/express), [dual](/topic/dual) **Top accounts mentioned or mentioned by** [@massgeneralnews](/creator/undefined) [@dglaucomflecken](/creator/undefined) [@harvardmed](/creator/undefined) [@efusebrown](/creator/undefined) [@srm128](/creator/undefined) [@ucsf](/creator/undefined) [@ahascience](/creator/undefined) [@escardio](/creator/undefined) [@adadiabetespro](/creator/undefined) [@brighamwomens](/creator/undefined) [@myesmo](/creator/undefined) [@asnkidney](/creator/undefined) [@coreimpodcast](/creator/undefined) [@atscommunity](/creator/undefined) [@lisarosenbaum17](/creator/undefined) [@harvardchansph](/creator/undefined) [@nejmcatalyst](/creator/undefined) [@nejmevidence](/creator/undefined) [@ashhematology](/creator/undefined) [@bidmchealth](/creator/undefined) ### Top Social Posts Top posts by engagements in the last XX hours "Presented at #KidneyWk: In the PISCES trial involving participants receiving hemodialysis fish oil (n3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: Editorial: Fish Oil for Patients Receiving Hemodialysis Red Herring or Great Catch @ASNKidney" [X Link](https://x.com/NEJM/status/1986834801106821591) 2025-11-07T16:35Z 932.8K followers, 192.1K engagements "Bedside clinical skills have been diminished by an overreliance on technology. A new Review Article presents educational strategies for reinvigorating the bedside encounter and shows how much can be learned from it. Read the review Strategies to Reinvigorate the Bedside Clinical Encounter the latest in the Medical Education series by Brian T. Garibaldi MD MEHP and Stephen W. Russell MD from @NUFeinbergMed and the University of Alabama at Birmingham (@UABNews):" [X Link](https://x.com/NEJM/status/1989815715147518279) 2025-11-15T22:00Z 932.8K followers, 92.7K engagements "Could clesrovimab a human RSV monoclonal antibody reduce the incidence of RSV infection in preterm and full-term infants Find out in the latest video in our partnership with @DGlaucomflecken. Read the full results of the CLEVER trial for free:" [X Link](https://x.com/NEJM/status/1990902838755504139) 2025-11-18T22:00Z 932.4K followers, 43.4K engagements "Presented at #SVIN25: CREST-2: In high-grade asymptomatic carotid stenosis addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: Editorial: Managing Asymptomatic Carotid Stenosis @svinsociety" [X Link](https://x.com/NEJM/status/1991893129390362880) 2025-11-21T15:35Z 932.8K followers, 382.4K engagements "Influenza remains an important cause of illness and death. In a phase X trial a nucleoside-modified mRNA (modRNA) quadrivalent vaccine was found to be superior to a standard quadrivalent vaccine in preventing influenza illness. Full trial results and Research Summary:" [X Link](https://x.com/NEJM/status/1992594122339922104) 2025-11-23T14:00Z 932.4K followers, 100.6K engagements "A 66-year-old man with COPD presented with a 2-week history of shortness of breath and cough and X days of left flank pain. Two days before presentation he had noted the appearance and rapid expansion of a mass on his left side. CT of the chest is shown. What is the underlying etiology" [X Link](https://x.com/NEJM/status/1995174247464124679) 2025-11-30T16:53Z 932.7K followers, 62.6K engagements "A 26-year-old woman presented with a 1-day history of a mobile serpiginous lesion in her left upper eyelid (shown in a video). She reported owning a dog. Read the full case details:" [X Link](https://x.com/NEJM/status/1995613959358218615) 2025-12-01T22:00Z 932.3K followers, 113.1K engagements "In a phase X trial single-dose CRISPR-Cas9 gene editing targeting ANGPTL3 led to reductions in ANGPTL3 protein levels with few adverse events. Full trial results:" [X Link](https://x.com/NEJM/status/1995855632344441049) 2025-12-02T14:00Z 932.7K followers, 28.3K engagements "Twelve former commissioners of the FDA express concern that the agencys recent moves will undermine a regulatory model designed to ensure vaccine safety effectiveness and availability. Read the full Perspective:" [X Link](https://x.com/NEJM/status/1996341178351092220) 2025-12-03T22:10Z 932.8K followers, 32.5K engagements "In a new trial one dose of an HPV vaccine was noninferior to two doses in preventing HPV type XX or XX infection. Full ESCUDDO trial results: Editorial: Evidence to Action Single-Dose HPV Vaccination and Cervical HPV Infection" [X Link](https://x.com/NEJM/status/1996342447379767750) 2025-12-03T22:15Z 932.8K followers, 15.7K engagements "A trial of pegcetacoplan a C3 and C3b inhibitor in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis showed that the drug significantly reduced proteinuria. Full VALIANT phase X trial results: Editorial: Pegcetacoplan for Treatment of C3 Glomerulopathy and Immune-Complex MPGN" [X Link](https://x.com/NEJM/status/1996346241643651573) 2025-12-03T22:30Z 932.8K followers, 13.5K engagements "Idiopathic normal-pressure hydrocephalus (iNPH) typically causes gait cognitive and urinary impairment. The diagnosis is aided by a medical evaluation imaging findings and tests that predict improvement with CSF shunting. Learn more in the Review Article Idiopathic Normal-Pressure Hydrocephalus by Mark D. Johnson MD PhD and Michael A. Williams MD from @UMassChan and @UWMedicine:" [X Link](https://x.com/NEJM/status/1996348731311219049) 2025-12-03T22:40Z 932.8K followers, 47.5K engagements "Immunizations against Covid-19 RSV and influenza have shown consistent effectiveness and safety and are associated with a substantially reduced risk of hospitalization and severe disease across populations. Findings from a @CIDRAP systematic review underscore the enduring value of immunization against respiratory viruses as a cornerstone of preventive care and support the feasibility of maintaining rigorous evidence-based guidance during periods of institutional disruption. Read the full article:" [X Link](https://x.com/NEJM/status/1996655919535739350) 2025-12-04T19:00Z 932.8K followers, 16.5K engagements "For a preclinical grading system in a medical school should you support the continuation of the five-tier grading system (A B C D F) or recommend implementation of a pass/fail system Read the case vignette treatment options and vote:" [X Link](https://x.com/NEJM/status/1996942808163488004) 2025-12-05T14:00Z 932.7K followers, 8490 engagements "Presented at #ASH25: In drug-resistant extramedullary myeloma dual treatment with talquetamab and teclistamab produced a response in XX% of patients and 12-month overall survival was 74%; however grade X or X adverse events were common. Full RedirecTT-1 phase 1b2 study results: @ASH_hematology" [X Link](https://x.com/NEJM/status/1997781922010079280) 2025-12-07T21:35Z 932.8K followers, 24.4K engagements "Original Article: Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN (VALIANT phase X trial) Editorial: Pegcetacoplan for Treatment of C3 Glomerulopathy and Immune-Complex MPGN #Nephrology" [X Link](https://x.com/NEJM/status/1998105447744827795) 2025-12-08T19:00Z 932.8K followers, 10.7K engagements "Presented at #ASH25: In relapsed or refractory T-cell acute lymphoblastic leukemia off-the-shelf allogeneic base-edited CAR7 T cells mediated responses in XX patients enabling stem-cell transplantation in X patients in deep remission. Full study results: @ASH_hematology" [X Link](https://x.com/NEJM/status/1998144320512397526) 2025-12-08T21:35Z 932.8K followers, 37.5K engagements "Which one of the following choices is the enzyme that is deficient in patients with Pompe disease" [X Link](https://x.com/NEJM/status/1998487060425118140) 2025-12-09T20:16Z 932.8K followers, 8008 engagements "A 26-year-old woman was referred to the pulmonary hypertension clinic with a 6-month history of exertional dyspnea and hoarseness. Vocal-fold paralysis was seen on laryngoscopy (shown in a video). Read the full case details:" [X Link](https://x.com/NEJM/status/1993409480445640739) 2025-11-25T20:00Z 932.8K followers, 636.8K engagements "New in the December X 2025 issue of NEJM: Glucocorticoids for Community-Acquired Pneumonia (SONIA trial) Shunting for Idiopathic Normal-Pressure Hydrocephalus (PENS trial) Pegcetacoplan in C3 Glomerulopathy and IC-MPGN (VALIANT phase X trial) Subscribe to NEJM for the latest medical research:" [X Link](https://x.com/NEJM/status/1996580404283994393) 2025-12-04T14:00Z 932.8K followers, 35.4K engagements "Treatments are needed for C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. Pegcetacoplan a targeted C3 and C3b inhibitor showed promise in phase X trials. Research findings from the VALIANT phase X trial are summarized in a new Quick Take video" [X Link](https://x.com/NEJM/status/1997758101613883813) 2025-12-07T20:00Z 932.8K followers, 14.4K engagements "Presented at #ASH25: In the VAYHIT2 phase X trial ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag with a stable platelet response at X months in a higher percentage of patients with X mg/kg of ianalumab than with placebo. Full trial results: @ASH_hematology" [X Link](https://x.com/NEJM/status/1998370810927714582) 2025-12-09T12:35Z 932.8K followers, 12.7K engagements "A new trial of pegcetacoplan a C3 and C3b inhibitor in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis showed that the drug significantly reduced proteinuria. Full VALIANT phase X trial results and Research Summary:" [X Link](https://x.com/NEJM/status/1998754758342095031) 2025-12-10T14:00Z 932.8K followers, 5460 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@NEJM NEJM
NEJM posts on X about events, history, red, education the most. They currently have XXXXXXX followers and XXX posts still getting attention that total XXXXXX engagements in the last XX hours.
Engagements: XXXXXX #
- X Week XXXXXXX -XX%
- X Month XXXXXXX -XXXX%
- X Months XXXXXXXXX +67%
- X Year XXXXXXXXX -XX%
Mentions: XX #
- X Month XX -XX%
- X Months XXX +106%
- X Year XXX +30%
Followers: XXXXXXX #
- X Week XXXXXXX +0.11%
- X Month XXXXXXX -XXXX%
- X Months XXXXXXX +0.03%
- X Year XXXXXXX -XXXX%
CreatorRank: XXXXXXX #
Social Influence
Social topic influence events #3138, history, red, education, reduce, what is, express, dual
Top accounts mentioned or mentioned by @massgeneralnews @dglaucomflecken @harvardmed @efusebrown @srm128 @ucsf @ahascience @escardio @adadiabetespro @brighamwomens @myesmo @asnkidney @coreimpodcast @atscommunity @lisarosenbaum17 @harvardchansph @nejmcatalyst @nejmevidence @ashhematology @bidmchealth
Top Social Posts
Top posts by engagements in the last XX hours
"Presented at #KidneyWk: In the PISCES trial involving participants receiving hemodialysis fish oil (n3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: Editorial: Fish Oil for Patients Receiving Hemodialysis Red Herring or Great Catch @ASNKidney"
X Link 2025-11-07T16:35Z 932.8K followers, 192.1K engagements
"Bedside clinical skills have been diminished by an overreliance on technology. A new Review Article presents educational strategies for reinvigorating the bedside encounter and shows how much can be learned from it. Read the review Strategies to Reinvigorate the Bedside Clinical Encounter the latest in the Medical Education series by Brian T. Garibaldi MD MEHP and Stephen W. Russell MD from @NUFeinbergMed and the University of Alabama at Birmingham (@UABNews):"
X Link 2025-11-15T22:00Z 932.8K followers, 92.7K engagements
"Could clesrovimab a human RSV monoclonal antibody reduce the incidence of RSV infection in preterm and full-term infants Find out in the latest video in our partnership with @DGlaucomflecken. Read the full results of the CLEVER trial for free:"
X Link 2025-11-18T22:00Z 932.4K followers, 43.4K engagements
"Presented at #SVIN25: CREST-2: In high-grade asymptomatic carotid stenosis addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: Editorial: Managing Asymptomatic Carotid Stenosis @svinsociety"
X Link 2025-11-21T15:35Z 932.8K followers, 382.4K engagements
"Influenza remains an important cause of illness and death. In a phase X trial a nucleoside-modified mRNA (modRNA) quadrivalent vaccine was found to be superior to a standard quadrivalent vaccine in preventing influenza illness. Full trial results and Research Summary:"
X Link 2025-11-23T14:00Z 932.4K followers, 100.6K engagements
"A 66-year-old man with COPD presented with a 2-week history of shortness of breath and cough and X days of left flank pain. Two days before presentation he had noted the appearance and rapid expansion of a mass on his left side. CT of the chest is shown. What is the underlying etiology"
X Link 2025-11-30T16:53Z 932.7K followers, 62.6K engagements
"A 26-year-old woman presented with a 1-day history of a mobile serpiginous lesion in her left upper eyelid (shown in a video). She reported owning a dog. Read the full case details:"
X Link 2025-12-01T22:00Z 932.3K followers, 113.1K engagements
"In a phase X trial single-dose CRISPR-Cas9 gene editing targeting ANGPTL3 led to reductions in ANGPTL3 protein levels with few adverse events. Full trial results:"
X Link 2025-12-02T14:00Z 932.7K followers, 28.3K engagements
"Twelve former commissioners of the FDA express concern that the agencys recent moves will undermine a regulatory model designed to ensure vaccine safety effectiveness and availability. Read the full Perspective:"
X Link 2025-12-03T22:10Z 932.8K followers, 32.5K engagements
"In a new trial one dose of an HPV vaccine was noninferior to two doses in preventing HPV type XX or XX infection. Full ESCUDDO trial results: Editorial: Evidence to Action Single-Dose HPV Vaccination and Cervical HPV Infection"
X Link 2025-12-03T22:15Z 932.8K followers, 15.7K engagements
"A trial of pegcetacoplan a C3 and C3b inhibitor in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis showed that the drug significantly reduced proteinuria. Full VALIANT phase X trial results: Editorial: Pegcetacoplan for Treatment of C3 Glomerulopathy and Immune-Complex MPGN"
X Link 2025-12-03T22:30Z 932.8K followers, 13.5K engagements
"Idiopathic normal-pressure hydrocephalus (iNPH) typically causes gait cognitive and urinary impairment. The diagnosis is aided by a medical evaluation imaging findings and tests that predict improvement with CSF shunting. Learn more in the Review Article Idiopathic Normal-Pressure Hydrocephalus by Mark D. Johnson MD PhD and Michael A. Williams MD from @UMassChan and @UWMedicine:"
X Link 2025-12-03T22:40Z 932.8K followers, 47.5K engagements
"Immunizations against Covid-19 RSV and influenza have shown consistent effectiveness and safety and are associated with a substantially reduced risk of hospitalization and severe disease across populations. Findings from a @CIDRAP systematic review underscore the enduring value of immunization against respiratory viruses as a cornerstone of preventive care and support the feasibility of maintaining rigorous evidence-based guidance during periods of institutional disruption. Read the full article:"
X Link 2025-12-04T19:00Z 932.8K followers, 16.5K engagements
"For a preclinical grading system in a medical school should you support the continuation of the five-tier grading system (A B C D F) or recommend implementation of a pass/fail system Read the case vignette treatment options and vote:"
X Link 2025-12-05T14:00Z 932.7K followers, 8490 engagements
"Presented at #ASH25: In drug-resistant extramedullary myeloma dual treatment with talquetamab and teclistamab produced a response in XX% of patients and 12-month overall survival was 74%; however grade X or X adverse events were common. Full RedirecTT-1 phase 1b2 study results: @ASH_hematology"
X Link 2025-12-07T21:35Z 932.8K followers, 24.4K engagements
"Original Article: Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN (VALIANT phase X trial) Editorial: Pegcetacoplan for Treatment of C3 Glomerulopathy and Immune-Complex MPGN #Nephrology"
X Link 2025-12-08T19:00Z 932.8K followers, 10.7K engagements
"Presented at #ASH25: In relapsed or refractory T-cell acute lymphoblastic leukemia off-the-shelf allogeneic base-edited CAR7 T cells mediated responses in XX patients enabling stem-cell transplantation in X patients in deep remission. Full study results: @ASH_hematology"
X Link 2025-12-08T21:35Z 932.8K followers, 37.5K engagements
"Which one of the following choices is the enzyme that is deficient in patients with Pompe disease"
X Link 2025-12-09T20:16Z 932.8K followers, 8008 engagements
"A 26-year-old woman was referred to the pulmonary hypertension clinic with a 6-month history of exertional dyspnea and hoarseness. Vocal-fold paralysis was seen on laryngoscopy (shown in a video). Read the full case details:"
X Link 2025-11-25T20:00Z 932.8K followers, 636.8K engagements
"New in the December X 2025 issue of NEJM: Glucocorticoids for Community-Acquired Pneumonia (SONIA trial) Shunting for Idiopathic Normal-Pressure Hydrocephalus (PENS trial) Pegcetacoplan in C3 Glomerulopathy and IC-MPGN (VALIANT phase X trial) Subscribe to NEJM for the latest medical research:"
X Link 2025-12-04T14:00Z 932.8K followers, 35.4K engagements
"Treatments are needed for C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. Pegcetacoplan a targeted C3 and C3b inhibitor showed promise in phase X trials. Research findings from the VALIANT phase X trial are summarized in a new Quick Take video"
X Link 2025-12-07T20:00Z 932.8K followers, 14.4K engagements
"Presented at #ASH25: In the VAYHIT2 phase X trial ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag with a stable platelet response at X months in a higher percentage of patients with X mg/kg of ianalumab than with placebo. Full trial results: @ASH_hematology"
X Link 2025-12-09T12:35Z 932.8K followers, 12.7K engagements
"A new trial of pegcetacoplan a C3 and C3b inhibitor in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis showed that the drug significantly reduced proteinuria. Full VALIANT phase X trial results and Research Summary:"
X Link 2025-12-10T14:00Z 932.8K followers, 5460 engagements